Not long after the FDA wrapped its preliminary investigation of GLP-1 receptor agonists and suicidal thoughts or actions, the ...

The analysis included five trials for DPP-4 inhibitors, eight for GLP-1 RAs, and 14 for SGLT2 inhibitors. The oldest trial was in 2013 and the most recent in 2023. The studies investigated ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and ...

This enhancement is linked to increased expression levels of GLP-1 receptors and intracellular ... shown to be complementary to metformin and SGLT2 inhibitors, two very commonly used agents ...

Researchers have discovered that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), often used for the treatment of type 2 diabetes (T2D), ...

The quest for effective weight loss solutions has never been more urgent, with millions of people worldwide struggling to ...

A substantial proportion of patients never filled prescriptions for recommended cardiovascular medications, with particularly low utilization of SGLT2 inhibitors and GLP-1 receptor agonists (90.9% ...

However the trial didn't demonstrate any extra 'synergistic' benefits in combining the drugs, which other GLP-1 plus SGLT2 inhibitor trials have shown. A trial of AstraZeneca's GLP-1 Bydureon ...

According to Ian Neeland, MD, strategies like pharmacist-led counseling, patient education programs, and patient assistance ...